finance.yahoo.comOct 13$JNJ

J&J beats earnings estimates; Middle East conflict weighs on medical device sales

Johnson & Johnson reported Q3 revenue of $25.4B, beating estimates, with strong pharmaceutical sales but slower medical device growth due to Middle East conflict and other geopolitical issues. Tremfya sales rose 68% to $2.4B, while Stelara sales fell 54% to $716M. The company raised its full-year sales and earnings forecasts. J&J shares have risen 27% this year.

Original reporting

finance.yahoo.com

Published Oct 13, 2026, 10:21 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 13, 2026, 10:32 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

J&J beats earnings estimates; Middle East conflict weighs on medical device sales — source image — Source · finance.yahoo.com

Decision brief

The 30-second read

$JNJNeutralHigh

Why it matters

The earnings beat and guidance raise provide a catalyst for short‑term buying, while the device segment weakness may limit upside.

Market read

First‑time earnings disclosure for a mega‑cap health‑care stock; new guidance and segment commentary are material for traders.

What to watch

Potential cost‑inflation from rising fuel prices and any upcoming regulatory approvals for J&J's pipeline could add upside.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Johnson & Johnson is a diversified health‑care conglomerate with pharma, medical devices, and consumer health businesses. The Q3 report reflects strong pharma growth and soft device performance amid geopolitical headwinds.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$JNJNeutralHigh confidence

Context

Johnson & Johnson posted Q3 earnings beat and raised full-year sales and EPS guidance, while noting Middle East conflict pressure on its medical devices segment.

Expected impact

likely modest upside as the market prices in the earnings beat and guidance raise, tempered by device‑segment concerns.

Evidence & confidence

The earnings numbers and guidance are new primary disclosures; the beat is modest and device sales are flat, so price reaction may be limited.

Market effects

Sector

Medical device and pharma peers may see mixed reactions; pharma segment strength could lift sector, while device concerns may weigh on peers with similar exposure.

Regional

Middle‑East geopolitical tension could pressure healthcare stocks with significant overseas exposure.

Global

Large‑cap health‑care earnings influence broader market sentiment, especially in defensive sectors.

Counterpoint

What could challenge this read

If device sales rebound faster than expected, the stock could outperform the modest earnings reaction.

Key entities

company
Johnson & Johnson
Diversified health‑care company reporting Q3 results.

Read at source ← All news

$ZBHHighAI 9/10

Zimmer Biomet Soars 15% as Hip and Tech Growth Lifts Guidance, “Validating the Progress” of Its Strategy

Zimmer Biomet (ZBH) shares rose 15% after Q3 sales grew 3.7% in constant currency, with hips, sports medicine, and technology segments growing 7% or more. The company raised its 2026 guidance, citing progress in diversification. Knees, 37% of sales, declined 2.6%. Rival Stryker (SYK) and Smith & Nephew (SNN) also saw gains, despite Smith & Nephew cutting its outlook.

finance.yahoo.comNov 4

$JNJMedAI 8/10

Johnson & Johnson’s Javelin Catheter Met Both Trial Goals and Its Impella Data Pushed Back on a Negative Study. Here’s What It Doesn’t Settle

Johnson & Johnson (JNJ) reported positive results for its Javelin catheter, meeting both primary goals in a pivotal study. Impella heart pump data showed lower death rates than a previous negative study. Javelin is still under FDA review, and Impella's recovery depends on future trials. JNJ's cardiovascular unit saw a sales decline, with Impella contributing 1.6% of total revenue. Analysts project a ~25% total return for JNJ stock.

finance.yahoo.comNov 2

$JNJMed

TREMFYA® (guselkumab) reimbursed for the treatment of moderately to severely active Crohn’s disease and ulcerative colitis for use in Ireland

Johnson & Johnson's TREMFYA (guselkumab) has been approved for reimbursement in Ireland for treating moderately to severely active Crohn’s disease and ulcerative colitis. The approval is based on Phase 3 trials showing significant clinical remission rates. According to the company, it offers a novel dual mechanism of action and improved outcomes for patients.

imt.ieNov 2

$JNJMed

J&J data show lower mortality with Impella in HRPCI than CHIP-BCIS3

Johnson & Johnson (J&J) presented data at a symposium showing lower mortality rates in high-risk PCI patients using Impella heart pumps compared to the CHIP-BCIS3 trial. Three analyses, involving 1,379 patients, reported 30-day mortality rates of 6.1% and 4.7%, and 90-day rates of 6.5%. J&J's heart recovery chief medical officer highlighted the importance of device usage and patient selection. The company continues studying Impella, with PROTECT IV trial results expected in 2027.

medicaldevice-network.comNov 2

$JNJMedAI 8/10

J&J's Javelin Meets Pivotal Coronary Study Goals; Highlights Impella Survival Data At TCT

Johnson & Johnson (JNJ) reported that its Shockwave Javelin coronary catheter met primary endpoints in the FORWARD CAD study, with 93.6% successful lesion crossing and 93.4% safety. The study involved 158 patients. Separately, J&J shared favorable Impella data from three analyses, showing low mortality rates. JNJ closed at $273.20, down 0.73%.

rttnews.comNov 2

$JNJHigh

PROTEUS: Perioperative Apalutamide Plus ADT Improves EFS in High-Risk Locally Advanced Prostate Cancer

A substudy of the phase 3 PROTEUS trial, presented at ESMO Congress 2026, showed that perioperative apalutamide plus ADT reduced recurrence or death risk by 62% in high-risk prostate cancer patients. The study, supported by Johnson & Johnson, met primary endpoints, including event-free survival and metastasis-free survival. Lead author Alberto Briganti suggested the treatment could become a standard option for eligible patients.

endocrinologyadvisor.comNov 2